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Vertebroplasty versus conservative treatment in acute 
osteoporotic vertebral compression fractures (Vertos II): 
an open-label randomised trial
Caroline A H Klazen, Paul N M Lohle, Jolanda de Vries, Frits H Jansen, Alexander V Tielbeek, Marion C Blonk, Alexander Venmans, 
Willem Jan J van Rooij, Marinus C Schoemaker, Job R Juttmann, Tjoen H Lo, Harald J J Verhaar, Yolanda van der Graaf, Kaspar J van Everdingen, 
Alex F Muller, Otto E H Elgersma, Dirk R Halkema, Hendrik Fransen, Xavier Janssens, Erik Buskens, Willem P Th M Mali
Summary
Background Percutaneous vertebroplasty is increasingly used for treatment of pain in patients with osteoporotic 
vertebral compression fractures, but the effi  cacy, cost-eff ectiveness, and safety of the procedure remain uncertain. We 
aimed to clarify whether vertebroplasty has additional value compared with optimum pain treatment in patients with 
acute vertebral fractures.
Methods Patients were recruited to this open-label prospective randomised trial from the radiology departments of six 
hospitals in the Netherlands and Belgium. Patients were aged 50 years or older, had vertebral compression fractures 
on spine radiograph (minimum 15% height loss; level of fracture at Th5 or lower; bone oedema on MRI), with back 
pain for 6 weeks or less, and a visual analogue scale (VAS) score of 5 or more. Patients were randomly allocated to 
percutaneous vertebroplasty or conservative treatment by computer-generated randomisation codes with a block size 
of six. Masking was not possible for participants, physicians, and outcome assessors. The primary outcome was pain 
relief at 1 month and 1 year as measured by VAS score. Analysis was by intention to treat. This study is registered at 
ClinicalTrials.gov, number NCT00232466.
Findings Between Oct 1, 2005, and June 30, 2008, we identifi ed 431 patients who were eligible for randomisation. 
229 (53%) patients had spontaneous pain relief during assessment, and 202 patients with persistent pain were 
randomly allocated to treatment (101 vertebroplasty, 101 conservative treatment). Vertebroplasty resulted in greater 
pain relief than did conservative treatment; diff erence in mean VAS score between baseline and 1 month was 
–5·2 (95% CI –5·88 to –4·72) after vertebroplasty and –2·7 (–3·22 to –1·98) after conservative treatment, and 
between baseline and 1 year was –5·7 (–6·22 to –4·98) after vertebroplasty and –3·7 (–4·35 to –3·05) after 
conservative treatment. The diff erence between groups in reduction of mean VAS score from baseline was 
2·6 (95% CI 1·74–3·37, p<0·0001) at 1 month and 2·0 (1·13–2·80, p<0·0001) at 1 year. No serious complications 
or adverse events were reported.
Interpretation In a subgroup of patients with acute osteoporotic vertebral compression fractures and persistent pain, 
percutaneous vertebroplasty is eff ective and safe. Pain relief after vertebroplasty is immediate, is sustained for at least 
a year, and is signifi cantly greater than that achieved with conservative treatment, at an acceptable cost.
Funding ZonMw; COOK Medical.
Introduction 
Vertebral compression fractures in osteoporosis are 
common in the elderly population, with an estimated 
1·4 million new fractures occurring every year 
worldwide.1 About a third of new fractures come to 
medical attention, suggesting that most are either 
asymptomatic or have tolerable symptoms.2 Patients 
with an acute vertebral fracture can present with severe 
back pain lasting for weeks to months. Until recently, 
bed rest, analgesia, and cast and physical support were 
the only treatment options. Vertebroplasty, involving 
percutaneous injection of bone cement into the fractured 
vertebral body, was introduced as an alternative option 
for treatment of pain. Since its introduction, this 
minimally invasive technique has gained widespread 
recognition, eff ectively reducing pain both in the short 
and long term.3–12 Two randomised studies with a sham 
control intervention have reported clinical outcomes 
1 month and 6 months after percutaneous vertebroplasty 
in patients with osteoporotic vertebral fractures up to a 
year old.13,14 Results of both studies seem to show that 
vertebroplasty and sham treatment are equally eff ective. 
However, clinical interpretation of these studies is 
hampered by inclusion of patients with subacute and 
chronic fractures instead of acute fractures, absence of a 
control group without intervention, inconsistent use of 
bone oedema on MRI as an inclusion criterion, and 
other methodological issues.15 We aimed to clarify 
whether percutaneous vertebroplasty has additional 
value compared with optimum pain treatment in a well 
defi ned group of patients with acute vertebral 
compression fractures.
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Methods
Study design and patients
The methods of this study, including the protocol, patient 
selection, and clinical outcome measures, have been 
described in detail elsewhere;16 in this Article, we mainly 
report on evolution of pain and cost-eff ectiveness of 
vertebroplasty. In short, we undertook an open-label 
randomised controlled trial in fi ve large teaching 
hospitals in the Netherlands and one in Belgium. Patients 
were recruited at the radiology departments of the 
participating centres. All patients aged 50 years or older 
who were referred by their general practitioner for spine 
radiography because of back pain were asked to complete 
a short questionnaire about presence, severity, and 
duration of pain by a nurse practitioner. Inclusion criteria 
were: vertebral compression fracture on spine radiograph 
(minimum 15% height loss); level of fracture at Th5 or 
lower; back pain for 6 weeks or less; visual analogue scale 
(VAS) score of 5 or more; bone oedema of vertebral 
fracture on MRI; focal tenderness at fracture level, as 
assessed by an internist on physical examination; and 
decreased bone density (T scores ≤–1). Exclusion criteria 
were: severe cardiopulmonary comorbidity; untreatable 
coagulopathy; systemic or local spine infection; suspected 
underlying malignant disease; radicular syndrome; 
spinal-cord compression syndrome; and contraindication 
for MRI. Eligible patients were contacted and requested 
to consider participation in the study. Patients who agreed 
to participate were referred to an internist who reassessed 
complaints, took an additional VAS score, and obtained 
written informed consent. The study protocol was 
approved by the institutional review board at each 
participating centre.
Procedures
Patients were randomly allocated to percutaneous 
vertebroplasty or conservative treatment by an 
independent central telephone operator using computer-
generated randomisation codes with a block size of six. 
Masking was not possible for participants, physicians, 
and outcome assessors. Percutaneous vertebroplasty was 
done on a single or biplane angiography system under 
fl uoroscopic guidance. After local infi ltration analgesia, 
two 11 or 13 gauge bone-biopsy needles were placed 
transpedicularly in the fractured vertebral body. 
Polymethylmetacrylate bone cement (Osteo-Firm, COOK 
Medical, Bloomington, IN, USA) was injected through 
bone-biopsy needles under continuous fl uoroscopic 
monitoring to identify local cement leakage or migration 
into the venous system towards the lungs. When 
necessary, additional analgesia was used at the discretion 
of the treating physician. In patients who had more than 
one fracture with bone oedema on MRI, all vertebral 
bodies were treated in one or more procedures. After the 
procedure, a CT scan of the treated vertebral bodies was 
done with 2 mm slices to identify cement leakage outside 
the vertebral body or other possible local complications.
Patients were clinically assessed at baseline (the day of 
vertebroplasty or, in patients assigned to conservative 
treatment, the day of randomisation), and at 1 day, 1 week, 
1 month, 3 months, 6 months, and 1 year afterwards. 
Through out follow-up, analgesia in both groups was indi-
vidually tailored in a stepwise manner from non-opiates to 
weak opiate derivatives and strong opiate derivatives. Pain 
treatment was categorised according to WHO classifi cation 
as 0 (no drugs), 1 (non-opiates—eg, paracetamol, non-
steroidal anti-infl ammatory agents), 2 (weak opiate 
derivatives), and 3 (strong opiate derivatives).17 All patients 
were prescribed bisphosphonates, calcium supple-
mentation, and vitamin D. Complications and adverse 
events were recorded. To identify new fractures during 
follow-up, spine radiographs were done at baseline, 
1 month, 3 months, and 1 year. Two radiologists 
independently undertook morphometric measure ments.18 
Disagreements were solved by consensus. A new vertebral 
fracture was defi ned as a decrease of at least 4 mm in 
vertical dimension.2 Treatment of new vertebral fractures 
was according to the initial assigned protocol.
The primary outcome was pain relief at 1 month and 
1 year, measured with a VAS score ranging from 0 (no 
pain) to 10 (worst pain ever).19 We defi ned clinically 
signifi cant pain relief as a decrease in VAS score from 
baseline of 3 points or more. Pain-free days were defi ned 
as days with a VAS score of 3 or lower. The secondary 
outcome was cost-eff ectiveness at 1 month and 1 year. 
Medical costs, time without burdensome pain, and quality-
adjusted survival time were recorded. Costs were indexed 
to 2008 (webappendix) and derived from hospital billing 
systems and costing guidelines issued by the Dutch health 
insurance board.20 Quality-adjusted life-years (QALYs) 
were estimated with the EuroQol-5 dimensions (EQ-5D) 
questionnaire.21,22 We assessed uncertainty with respect 
to the incremental cost-eff ectiveness ratio using 
bootstrapping. The tertiary outcome was quality of life 
measured with the Quality of Life Questionnaire of the 
European Foundation for Osteoporosis (QUALEFFO),23 
and physical function measured with the Roland Morris 
Disability (RMD) questionnaire.24 Standard questionnaires 
including additional questions about pain treatment, 
hospital stay, outpatient visits, and medical aids were fi lled 
in with the help of a nurse practitioner.
Statistical analysis
On the assumption of a 25% diff erence in signifi cant 
pain relief and 20% withdrawals from vertebroplasty, 
100 patients were needed in each group (α=0·05 and 
β=0·20). Endpoints were compared by intention-to-treat 
analysis. We compared proportions of adverse events, 
drugs, and baseline fractures using χ² tests. p values are 
two-sided. Diff erences in mean VAS scores between 
baseline and 1 month and 1 year were assessed with the 
paired t test. We used analysis of variance for repeated 
measures to examine pain relief, quality of life, and 
physical function over time. Missing data for pain, 
See Online for webappendix
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EQ-5D, QUALEFFO, and RMD scores were imputed 
with linear interpolation and last observation carried 
forward. Imputation of missing data increased the power, 
but did not aff ect the results. In concordance with the 
study protocol, we analysed signifi cant pain relief over 
time using a Kaplan-Meier survival analysis. We estimated 
QALYs by calculating the individual area under the curve 
of the summary score. Imbalances at baseline were 
adjusted with linear regression analysis. We defi ned cost-
eff ectiveness as the ratio of diff erence in costs and 
diff erence in QALYs and the diff erence in pain-free days. 
SPSS (version 15.0.1) was used for all analyses.
This trial is registered at ClinicalTrials.gov, number 
NCT00232466.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, writing 
of the report, or the decision to submit for publication. 
The corresponding author had full access to the data and 
the fi nal responsibility to submit for publication.
Results
Between Oct 1, 2005, and June 30, 2008, 934 patients 
were screened for eligibility, of whom 202 were randomly 
allocated to treatment (101 percutaneous vertebroplasty, 
101 conservative treatment). Figure 1 shows the trial 
profi le. Patients allocated to vertebroplasty were treated 
at a mean of 9·4 (SD 8·1) days after randomisation. 
Table 1 shows baseline characteristics of both groups. 
Informed consent was withdrawn after randomisation by 
six patients assigned to conservative treatment and by 
two patients assigned to vertebroplasty. Since these 
patients were not attended in any of the study centres, 
treatment choice was unknown and follow-up could not 
be obtained. Six patients assigned to vertebroplasty did 
not receive the procedure because their health deteriorated 
before treatment (n=3) or they had spontaneous pain 
relief (n=3). Follow-up information was obtained for fi ve 
of these patients. Ten patients assigned to conservative 
treatment with ongoing invalidating pain requested and 
received vertebroplasty during follow-up. 163 (81%) 
participants completed 1 year of follow-up.
98 patients underwent vertebroplasty on 134 vertebrae 
in 103 procedures that took place a mean of 5·6 weeks 
(SD 2·9 weeks; range 4–92 days) after onset of 
symptoms. Mean volume of injected cement per 
vertebral body was 4·1 mL (SD 1·5; range 1–9). In one 
vertebral body, the second needle could not be placed 
properly and cement was injected at one side of the 
vertebra only. In 31 (30%) procedures, patients received 
additional intravenous analgesia. Two patients 
required atropine because of pain-induced vasovagal 
reaction. One patient developed an acute asthma 
exacerbation during vertebroplasty that led to stopping 
of the procedure. The procedure was successfully done 
1 week later.
Figure 1: Trial profi le
PV=percutaneous vertebroplasty. *Visual analogue scale score lower than 5 at consultation with internist, and thus 
no longer met inclusion criteria for randomisation.
934 patients screened
202 randomised
101 assigned to PV 101 assigned to conservative treatment
95 received treatment
94 completed 1 day follow-up
93 completed 1 week follow-up
92 completed 1 month follow-up
86 completed 3 months’ follow-up
81 completed 6 months’ follow-up
77 completed 1 year follow-up
1 died (old age)
93 received treatment
98 completed 1 day follow-up
97 completed 1 week follow-up
96 completed 1 month follow-up
92 completed 3 months’ follow-up
89 completed 6 months’ follow-up
86 completed 1 year follow-up
1 could not comply
1 died (cardiac failure)
3 could not comply
1 depression
1 could not comply
5 requested PV
3 could not comply
2 died (cardiac failure)
1 could not comply
2 died (cardiac failure, 
old age)
226 did not meet inclusion criteria





3 spontaneous pain relief
3 refused PV
4 could not comply
1 dementia
1 died (gastric bleeding)
2 could not comply
3 dementia
1 could not comply
1 could not comply2 PV
4 PV
2 PV
4 died (respiratory 
insufficiency, sepsis, 
cardiac failure, old age)
2 PV
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CT scanning of the 134 treated vertebral bodies 
showed cement leakage in 97 (72%). Most leakages 
were discal or into segmental veins; none were into the 
spinal canal. All patients remained asymptomatic. 
Fluoroscopy showed cement migration into the venous 
system towards the lungs in one patient (1%). This 
patient also remained asymptomatic and a follow-up 
chest CT after 1 year showed no perifocal infl ammatory 
pulmonary changes.
After a mean follow-up of 11·4 months (median 12·0, 
range 1–24), 18 new fractures were reported in 15 of 
91 patients treated with vertebroplasty and 30 new 
fractures in 21 of 85 conservatively treated patients. This 
diff erence was not signifi cant (p=0·44). 12 patients 
refused follow-up radiographs.
Baseline VAS scores were similar in both groups 
(table 1). Figure 2 shows reduction in VAS score during 
follow-up in both groups. Decrease in VAS score after 
vertebroplasty was signifi cantly higher than with 
conservative treatment at all timepoints (F=127·5; 
p<0·001; power 1·0). The improved pain relief after 
vertebroplasty was apparent from 1 day after the 
procedure (mean VAS score 3·7 [SD 2·4] vs 6·7 [2·1]; 
p<0·0001) and remained signifi cant at 1 week (3·5 [2·5] 
vs 5·6 [2·5]; p<0·0001), 1 month (2·5 [2·5] vs 4·9 [2·6]; 
p<0·0001), 3 months (2·5 [2·7] vs 3·9 [2·8]; p=0·025), 
6 months (2·3 [2·7] vs 3·9 [2·9]; p=0·014), and 1 year 
(2·2 [2·7] vs 3·8 [2·8]; p=0·014).
After vertebroplasty, the diff erence in mean VAS score 
between baseline and 1 month was –5·2 (95% CI 
–5·88 to –4·72), and between baseline and 1 year was 
–5·7 (–6·22 to –4·98). After conservative treatment, the 
diff erence in mean VAS score from baseline was –2·7 
(–3·22 to –1·98) at 1 month and –3·7 (–4·35 to –3·05) 
at 1 year. The diff erence between groups in reduction of 
mean VAS score from baseline was 2·6 (1·74 to 3·37, 
p<0·0001) at 1 month, and 2·0 (1·13 to 2·80, p<0·0001) 
at 1 year. Survival analysis showed that signifi cant pain 
relief (χ²=55·6, p<0·0001) was achieved earlier and in 
more patients after vertebroplasty (29·7 days until 
signifi cant pain relief, 95% CI 11·45–47·97) than with 
conservative treatment (115·6 days, 95% CI 
85·87–145·40; fi gure 3).
At baseline, the class of drugs used for pain relief was 
similar in both groups. After vertebroplasty, use of 
drugs was signifi cantly reduced compared with 
conservative treatment at 1 day (p<0·0001), 1 week 
(p=0·001), and 1 month (p=0·033). This diff erence was 
not signifi cant at later stages of follow-up. At baseline, a 
signifi cantly lower EQ-5D score was recorded in the 
vertebroplasty group than in the conservative treatment 
group (table 1). This diff erence had to have been caused 
by chance. After adjustment for baseline use with 
regression analysis, the diff erence in QALYs favouring 
the vertebroplasty group was 0·010 (95% CI 
0·014–0·006) at 1 month and 0·108 (0·177–0·040) at 1 
year. Both QUALEFFO and RMD scores at baseline 
were signifi cantly worse for the vertebroplasty group 
than for the conservative treatment group (table 1). 
Improvement with time was signifi cantly greater and 
quicker after vertebroplasty than with conservative 
treatment, for both QUALEFFO (p<0·0001) and RMD 
(p<0·0001) (fi gure 2).
The diff erence between treatments in mean total medical 
costs per patient was €2474 at 1 month and €2450 at 1 year, 
in favour of conservative treatment (table 2). The higher 
costs for vertebroplasty compared with conservative 
treatment at both intervals were roughly equivalent to the 
cost of the procedure (€2463). During the fi rst year after 
vertebroplasty, an average 120·3 (95% CI 163·2–77·4) pain-
free days were gained. The cost of one pain-free day gained 
was €20. The adjusted trial-based incremental cost-
eff ectiveness ratio for vertebroplasty, as compared with 
conservative treatment, was €22 685 per QALY gained. 
Incremental costs and eff ects were adjusted for each 
bootstrap sample and the adjusted estimates were displayed 
in a cost-eff ectiveness plane (fi gure 4). These results were 





Age (years) 75·2 (9·8) 75·4 (8·4)
Sex (female) 70 (69%) 70 (69%)
Duration of back pain (days) 29·3 (17·1) 26·8 (16·0)
Initial VAS score 7·8 (1·5) 7·5 (1·6)
Number of VCFs at baseline 2·4 (1·9)* 2·1 (1·5)*
Number and grading of VCFs with bone oedema†
Mild (10–20%) 57 (42%) 55 (46%)
Moderate (20–40%) 58 (43%) 45 (38%)
Severe (>40%) 21 (15%) 20 (17%)
Wedge 90 (66%) 97 (81%)
Biconcave 46 (34%) 23 (19%)
Crush 0 0
Initial pain treatment
None 5 (5%) 7 (7%)
Non-opiate drugs 40 (40%) 43 (43%)
Weak opiate derivatives 31 (31%) 22 (22%)
Strong opiate derivatives 19 (19%) 20 (20%)
Vertebral level with bone oedema
Th5–Th10 19 (14%) 32 (25%)
Th11–L2 91 (65%) 66 (52%)
L3–L5 29 (21%) 28 (22%)
Use of osteoporosis drugs 24 (24%) 26 (26%)
Bone density T score –3·0 (1·17) –3·0 (1·05)
EQ-5D score 0·27 (0·03) 0·38 (0·03)
QUALEFFO score 58·7 (13·5) 54·7 (14·4)
RMD score 18·6 (3·6) 17·2 (4·2)
Data are mean (SD) or number (%). VAS=visual analogue scale. VCF=vertebral compression fracture. EQ-5D=EuroQol-5 
dimensions. QUALEFFO=Quality of Life Questionnaire of the European Foundation for Osteoporosis. *Range 1–5. 
†Percentages are proportion of total number of VCFs (136 in percutaneous vertebroplasty group, 120 in conservative 
treatment group).
Table 1: Baseline characteristics
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curve (fi gure 4). The curve shows that if society were willing 
to spend €30 000 or more per QALY gained, vertebroplasty 
is an acceptable treatment strategy, with more than 
70% certainty.
Figure 2: Analysis of variance models for VAS (A), QUALEFFO (B), and RMD scores (C) in vertebroplasty and conservative treatment groups during follow-up
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One patient had urinary tract infection after 
vertebroplasty, and one patient had an asymptomatic 
cement deposition in a segmental pulmonary artery. 
11 patients died of unrelated causes during follow-up: 
fi ve in the vertebroplasty group and six in the 
conservative treatment group (fi gure 1). One patient in 
the conservative treatment group who died from 
gastrointestinal bleeding used morphine as their only 
pain drug.
Discussion
Our results show that in patients with acute osteoporotic 
vertebral fractures who have persistent severe pain, 
vertebroplasty done at a mean 5·6 weeks after onset of 
symptoms resulted in quicker and greater pain relief 
than did conservative treatment. Notably, in more than 
half of the patients who initially qualifi ed for the study, 
pain spontaneously decreased to bearable levels, with a 
VAS score lower than 5 thereby precluding inclusion. 
After vertebroplasty, patients had signifi cant pain relief 
and used a lower class of drugs than did those receiving 
conservative treatment, or no drugs at all. Pain relief was 
sustained throughout follow-up. With conservative 
treatment, pain relief was slower and less than with 
vertebroplasty, and pain treatment required tended to 
increase during the fi rst month. Selection of optimum 
pain treatment and the psychological eff ect of care and 
daily attention accounted for the decrease in VAS score 
in the conservative treatment group during the fi rst week. 
The Kaplan-Meier survival curve confi rmed that 
signifi cant pain relief was achieved earlier after 
vertebroplasty than with conservative treatment.
In all patients in both groups, use of analgesic drugs 
was individually tailored and corrections in dose and 
class of drugs were made on a day-to-day basis. This 
strategy implies that the improved pain relief after 
vertebroplasty compared with conservative treatment is 
due to the procedure itself, and not to diff erences in 
drugs used. The increased pain relief after vertebroplasty 
remained signifi cant throughout a year of follow-up. This 
fi nding is remarkable, since fracture healing in the 
control group should be completed within several 
months. However, some patients in the control group 
developed chronic back pain, possibly because of non-
healing of the fracture. Future research could be aimed at 
identifi cation of these patients. With vertebroplasty, no 
serious complications occurred. This fi nding is in line 
with other studies.3,12 Minor cement leakage was 
frequently noted on CT scan, but leakage was 
asymptomatic in all cases. During follow-up, the 
incidence of new fractures after vertebroplasty and after 
conservative treatment was similar. This fi nding is in 
concordance with results of some other studies.3,25
Incremental costs of vertebroplasty roughly equalled 
procedural costs, but because of substantial interindivi-
dual variability with time, especially in the control group, 
the diff erence was no longer signifi cant at 1 year. We did 
not include costs of care by family or professionals at 
home in our analysis. Since these resources are 
particularly used in case of continued pain and loss of 
function they will probably play a more important part in 
the conservative treatment group. Data for costs and cost-
eff ectiveness are only valid in the Netherlands and might 
diff er for other countries. The resulting incremental cost-
eff ectiveness suggests that vertebroplasty seemed 
warranted for the patients with vertebral fractures treated 
at a mean 5·6 weeks after start of symptoms.











































Drugs, 1 month €24·36 (33·61) €43·51 (50·93) 0·003
Drugs, 1 year €204·88 (368·47) €280·47 (352·89) 0·15
Family doctor, 1 month €23·40 (49·16) €14·13 (35·70) 0·14
Family doctor, 1 year €970·30 (1167·49) €900·11 (1386·70) 0·70
Medical specialist, 1 month €46·08 (96·56) €68·87 (169·53) 0·25
Medical specialist, 1 year €2263·82 (3220·02) €2138·99 (3558·86) 0·80
Physiotherapist, 1 month €47·77 (71·71) €16·68 (49·18) 0·001
Physiotherapist, 1 year €694·72 (1249·80) €640·69 (1331·45) 0·77
Hospital admission, 1 year €2270·62 (9084·55) €2006·44 (10 081·68) 0·85
PV (including MRI spine, CT spine, day care)* €2339·60 (542·34) €233·43 (725·43) <0·0001
Total costs 1 month €2611·89 (148·07) €383·78 (745·66) <0·0001
Total costs 1 year €9182·78 (10 779·20) €6327·45 (11 872·79) 0·087
Data are mean (SD). All patients assigned to percutaneous vertebroplasty (PV; who received the procedure or not) for 
whom information about costs were available were included in this analysis. *PV costs appear in both columns because 
several patients assigned to conservative treatment received PV.
Table 2: Direct medical costs
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Our study as the fi rst open-label randomised controlled 
trial with mid-term follow-up to compare vertebroplasty 
with conservative treatment in patients with acute 
osteoporotic vertebral fracture. Results of a systematic 
literature review suggested that vertebroplasty eff ectively 
relieved pain;12 however, the included prospective and 
retrospective follow-up studies did not include control 
groups for comparison. Improvements in VAS scores that 
have been reported previously were in concordance with 
our results. In the VERTOS I study, a small group of 
patients with subacute vertebral compression fractures 
who were randomly allocated to vertebroplasty had 
immediate pain relief and improved mobility during 
short-term follow-up.26 The results were similar to ours, 
but the study was stopped early because of many 
crossovers. In our study, only 10% of patients assigned to 
conservative treatment crossed over to vertebroplasty.
Two randomised studies reported clinical outcomes after 
vertebroplasty compared with a sham procedure in patients 
with osteoporotic vertebral compression fractures.13,14 
Improvements in pain and pain-related disability were 
similar in both groups. The sham-controlled studies 
diff ered in two important ways from our study. First, we 
focused on acute fractures, whereas the sham-controlled 
studies included subacute fractures up to a year old. 
Second, by contrast with our study, bone oedema on MRI 
was not a consistent inclusion criterion. These diff erences 
might account for the small mean gain in VAS score in the 
sham-controlled studies compared with both our study 
and the fi ndings of the 2008 meta-analysis.12 Apparently, 
vertebroplasty at a mean 5·6 weeks after onset of symptoms 
is more eff ective for pain relief than is treatment up to a 
year after onset. Finally, the sham-controlled studies did 
not have a control group without intervention, and the best 
treatment option remains unclear for the clinician. Our 
study compared vertebroplasty with the reference treatment 
and thus provides the clinician with directly applicable 
information about how to best treat the patient.
The FREE study25 compared kyphoplasty with non-
surgical care in 300 patients with acute vertebral 
compression fractures. Instead of direct cement injection 
into the vertebral body, as in vertebroplasty, kyphoplasty 
involves use of an infl atable bone tamp that forms a space 
in the vertebral body into which cement can be injected. 
This method is regarded to be in competition with 
percutaneous vertebroplasty. The design of the FREE 
study was similar to that of our study, with kyphoplasty 
used instead of vertebroplasty. Kyphoplasty had a similar 
favourable eff ect on pain relief as did vertebroplasty in 
our study, with rapid and sustained improvement. Also, 
pain relief in conservatively treated patients was in the 
same range. An advantage of vertebroplasty is that the 
procedure can be done on an outpatient basis with local 
analgesia, whereas kyphoplasty requires general 
anaesthesia and hospital admission.27 Additionally, 
kyphoplasty can generate procedural costs that are up to 
20 times higher than those of vertebroplasty.28
The main drawback of our study was that treatment 
could not be masked. Knowledge of the treatment 
assignment might have aff ected patient responses to 
questions or radiologist assessments. Time needed for 
planning of vertebroplasty resulted in mean delay of 9 days 
until start of treatment compared with conservative 
treatment. We believe that this small diff erence in natural 
course was unlikely to have aff ected outcomes at 1 month 
and 1 year. In conclusion, in a selected subgroup of patients 
with acute osteoporotic vertebral fractures and persistent 
pain, vertebroplasty is eff ective and safe. Pain relief after 
the procedure is immediate, sustained for 1 year, and is 
signifi cantly better than that achieved with conservative 
treatment and at acceptable costs, on the assumption of a 
societal willingness to pay €30 000 per QALY gained.
Figure 4: Cost-eff ectiveness of vertebroplasty compared with conservative treatment
(A) Scatterplot of adjusted point estimates of incremental cost-eff ectiveness ratios. (B) Adjusted cost-eff ectiveness 
acceptability curve.
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